首页> 美国卫生研究院文献>Molecular Cancer >Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
【2h】

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

机译:嵌合抗原受体修饰的T细胞在肿瘤治疗中的研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies. This phenomenon has induced intense interest to develop CAR-T cell therapy for cancer, especially for solid tumors. However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease. Clinical studies on some neoplasms, such as glioblastoma, ovarian cancer, and cholangiocarcinoma, have achieved desirable outcome. This review describes the history and evolution of CAR-T, generalizes the structure and preparation of CAR-T, and summarizes the latest advances on CAR-T cell therapy in different tumor types. The last section presents the current challenges and prospects of CAR-T application to provide guidance for subsequent research.
机译:在医学领域,肿瘤治疗仍然很复杂。肿瘤免疫治疗一直是癌症治疗中最有趣的研究领域。嵌合抗原受体T(CAR-T)细胞疗法的应用最近在患者,尤其是CD19阳性血液系统恶性肿瘤的患者中取得了出色的临床效果。这种现象引起了人们对开发用于癌症,尤其是实体瘤的CAR-T细胞疗法的浓厚兴趣。但是,CAR-T细胞在实体瘤中的治疗效果不如血液系统疾病令人满意。对某些肿瘤(例如胶质母细胞瘤,卵巢癌和胆管癌)的临床研究已取得理想的结果。这篇综述描述了CAR-T的历史和进化,概述了CAR-T的结构和制备,并总结了CAR-T细胞治疗不同肿瘤类型的最新进展。最后一部分介绍了CAR-T应用的当前挑战和前景,为后续研究提供指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号